A BLA gets described as “the NDA for biologics,” and for a lot of practical purposes — review timelines, meeting requests, the general shape of the submission — that shorthand holds up well enough. It breaks down at the points that actually matter for regulatory affairs: which statute the product is licensed under, which FDA center reviews it, and what the license itself legally covers. None of those three track an NDA exactly, and treating a BLA as an NDA with extra biology attached is where the mechanics stop matching the shorthand.
Why the license covers the facility, not just the product
An NDA approves a drug; the manufacturing site gets inspected as part of that review, but the approval attaches to the application itself. A BLA historically split that in two: a Product License Application for the biologic, and a separate Establishment License Application for the facility that made it. The FDA Modernization Act of 1997 eliminated the second filing, folding manufacturing-site information into a single BLA that licenses the product and the facility together. That isn’t just a paperwork simplification. For a biologic, the manufacturing process is part of what defines the product — change the process meaningfully and you may have changed the product — so a license that treats the two as inseparable reflects something real about how biologics are regulated, not only how FDA files the forms.
Why the center matters
FDA review responsibility for biologics splits across two centers, and the split isn’t static. On June 30, 2003, FDA transferred review of most therapeutic biological products — monoclonal antibodies for in-vivo use and therapeutic proteins among them — from the Center for Biologics Evaluation and Research (CBER) to the Center for Drug Evaluation and Research (CDER). CBER kept the products closest to its original mandate: vaccines, blood and blood products, gene therapy, and most cellular and allergenic products. A regulatory affairs professional who assumes a biologic defaults to CBER review because it’s “a biologic” is working from a map that’s more than two decades out of date. How FDA decides which center reviews your product covers the broader logic FDA uses to make that call.
Where people get this wrong
Assuming CBER reviews every biologic
Most therapeutic proteins and monoclonal antibodies moved to CDER in 2003. Check current product jurisdiction rather than assuming by product class.
Treating facility information as separate from the BLA
Since the 1997 Modernization Act, the license covers the product and the manufacturing site together. There’s no separate establishment filing to track on its own.
Looking for the biologic in the Orange Book
The Orange Book lists NDA and ANDA drug products, not licensed biologics. Biologics and biosimilars live in a separate FDA list — how to read FDA’s Orange Book covers what does and doesn’t appear there.
The habit worth building is treating “biologic” as a signal to check, not assume: which statute, which center, and which list the product shows up on all answer differently than they would for a small-molecule drug. Get those three right early, and the rest of the submission — covered from the clinical side in how to read an IND application — follows a process that looks, from a distance, a lot like an NDA’s.
Sources & further reading
- 42 U.S.C. § 262, Public Health Service Act Section 351 law.cornell.edu
- 21 CFR § 601.2, Applications for biologics licenses; procedures for filing law.cornell.edu
- FDA — Transfer of Therapeutic Biological Products to the Center for Drug Evaluation and Research fda.gov
- Regulatory Academy — How FDA Decides Which Center Reviews Your Product regulatoryacademy.com
- Regulatory Academy — How to Read an IND Application regulatoryacademy.com
- Regulatory Academy — How to Read FDA’s Orange Book regulatoryacademy.com
This essay is provided for general educational purposes and reflects the regulatory landscape as of its publication date. It is not legal, regulatory, or career advice.
